$56,144.99 research Payment -- Bayer Healthcare to Dr. Nicole Lopez

Oncology Researcher Nicole Lopez Receives Over $56,000 in Research Payments from Bayer Healthcare

This page provides a detailed analysis of a $56,144.99 research payment from Bayer Healthcare to Dr. Nicole Lopez. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$56,144.99
Payment Typeresearch
Payment NatureResearch
Pharmaceutical CompanyBayer Healthcare
PhysicianDr. Nicole Lopez
NPI Number1871686539
Physician SpecialtyOncology
LocationCity, WI
Date of Payment2025-11-18
Related Drug/DeviceSkyrizi
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Bayer Healthcare made a $56.1K research payment to Nicole Lopez, a Oncology specialist in City, WI. The payment was associated with Skyrizi. Nicole Lopez received a substantial research payment of $56,144.99 from Bayer Healthcare for research related to Skyrizi. The payment was made on November 18, 2025, indicating a recent or future research collaboration. This payment falls under the 'research' category, suggesting it supports clinical trials or studies.

Patient Guidance: What This Payment Means for You

This payment supports research that may lead to new or improved cancer treatments. Ask your doctor if you are participating in any clinical trials. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Research payments to oncologists can be substantial, reflecting the significant investment in developing new cancer therapies. This amount is within the expected range for large-scale research studies.

Regulatory Context: Sunshine Act Requirements

Payments for research must be documented and disclosed under the Sunshine Act to ensure transparency in financial relationships between healthcare providers and pharmaceutical companies.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $56.1K payment for?

This was a research payment of $56.1K from Bayer Healthcare to Nicole Lopez, categorized as "Research". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Nicole Lopez accept pharmaceutical money?

Yes, Nicole Lopez received this $56.1K payment from Bayer Healthcare. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Nicole Lopez's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $56.1K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Nicole Lopez's relationship with Bayer Healthcare?

The payment amount is significant, suggesting a substantial research project. This $56.1K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The payment is specifically for 'research' activities, not for consulting or speaking.

What should patients do after learning about this payment?

This payment supports research that may lead to new or improved cancer treatments. Ask your doctor if you are participating in any clinical trials.

What else should I know about this research payment?

The drug associated with the payment is Skyrizi, a known therapeutic agent.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.